DS0404 - Innovation biomédicale

Role of TRAnsglutaminase 2 in IgA Nephropathy – TRAIN

Submission summary

IgA nephropathy (IgAN) is one of the major glomerulonephritis, leading to dialysis and transplantation for 30% of patients. This disease is characterized by IgA deposits in the glomeruli and circulating IgA with abnormal glycosylation involving IgA receptors. An enzyme: the transglutaminase 2 (TG2) is overexpressed in the glomeruli of IgAN patients and humanized mouse model. The absence of TG2 lead to a decreased of IgA deposits in mice. However, the exact role of the TG2 in IgAN is unknown. We will address the TG2 activity in the glomeruli as its crosslinking activity could stabilize the IgA complexes with their receptors. Moreover, preliminary results seem to show that the TG2 acts also on the formation of circulating IgA complexes in the disease. In the second part of the project, we will study this mechanism and produce a mouse overexpressing TG2. Finally, blocking the activity of this enzyme will be tested in order to potentially use this inhibition as therapy.

Project coordination

Laureline BERTHELOT (INSERM U1149)

The author of this summary is the project coordinator, who is responsible for the content of this summary. The ANR declines any responsibility as for its contents.

Partner

CRI INSERM U1149

Help of the ANR 186,392 euros
Beginning and duration of the scientific project: October 2014 - 36 Months

Useful links

Explorez notre base de projets financés

 

 

ANR makes available its datasets on funded projects, click here to find more.

Sign up for the latest news:
Subscribe to our newsletter